Viking Therapeutics Inc (NASDAQ:VKTX) shares, rose in value on Thursday, March 27, with the stock price down by -0.80% to the previous day’s close as strong demand from buyers drove the stock to $26.13.
Actively observing the price movement in the last trading, the stock closed the session at $26.34, falling within a range of $26.09 and $27.23. The value of beta (5-year monthly) was 0.897. Referring to stock’s 52-week performance, its high was $85.20, and the low was $24.41. On the whole, VKTX has fluctuated by -6.07% over the past month.
With the market capitalization of Viking Therapeutics Inc currently standing at about $2.93 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-04.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that VKTX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of VKTX currently trading nearly -8.22% and -14.36% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 38.92, while the 7-day volatility ratio is showing 5.96% which for the 30-day chart, stands at 7.32%. Furthermore, Viking Therapeutics Inc (VKTX)’s beta value is 0.78, and its average true range (ATR) is 2.07.
A comparison of Viking Therapeutics Inc (VKTX) with its peers suggests the former has fared considerably weaker in the market. VKTX showed an intraday change of -0.80% in last session, and over the past year, it shrunk by -62.23%%.
Data on historical trading for Viking Therapeutics Inc (NASDAQ:VKTX) indicates that the trading volumes over the past 10 days have averaged 3.18 and over the past 3 months, they’ve averaged 4.36 million. According to company’s latest data on outstanding shares, there are 111.57 million shares outstanding.
Nearly 2.94% of Viking Therapeutics Inc’s shares belong to company insiders and institutional investors own 73.48% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 24.21 million shares as on 2025-03-14, resulting in a short ratio of 4.34. According to the data, the short interest in Viking Therapeutics Inc (VKTX) stood at 2890.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 25.11 million. The stock has fallen by -35.06% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VKTX stock heading into the next quarter.
